Tamoxifen Citrate (Synonyms: ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate)

Name: Tamoxifen Citrate
Brand: MedChemExpress
SKU: HY-13757
Rating: 5.0 (229 reviews)

Cat. No.: HY-13757 Purity: 99.88%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Tamoxifen

Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice.

For research use only. We do not sell to patients.

CAS No. : 54965-24-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 229 publication(s) in Google Scholar

Other Forms of Tamoxifen Citrate:

229 Publications Citing Use of MCE Tamoxifen Citrate

Flow Cytometry

In Vivo Efficacy Study

Histological Imaging/Staining

IHC

Cell Imaging/Staining

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]; Peripheral blood chimerism (%Cd45.2) in mice engrafted with WT (Cd45.1) and Flt3^Frt-ITD (Cd45.2) cells following treatment with Tamoxifen (4 mg/mouse; p.o.) (red) or control (black).

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]; Flt3^Frt-ITD (red), Dnmt3a^Lox-R878H-Flt3^Frt-ITD (orange), and Npm1^Frt-c-Flt3^Frt-ITD (green) bone marrow was transplanted into lethally irradiated hosts. Kaplan-Meier survival plot following TAM (4 mg/mouse; p.o.).

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]; Bone marrow H&E from either control mice or after 7 days of TAM (4 mg/mouse; p.o.).

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]; Immunohistochemical staining on bone marrow for Ki67 (left) and phopsho-ERK1/2 (right) for untreated (top) and 7-day TAM (4 mg/mouse; p.o.) treated (bottom) Npm1^Lox-C-Flt3^GL-ITD mice.

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2099-2114. [Abstract]; Tamoxifen (2 mg/day; i.p.; for 5 consecutive days) can effectively induce the removal of NAT1 in various tissues, including muscle, white adipose tissue, pancreas, and liver, in adult Nat1^fl/fl;UBC^creERT2/+ mice and in Nat1^fl/fl;UBC^creERT2/+;Ripk1^D138N/D138N mice carrying a RIPK1 allele with an inactivation mutation.

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Nov 15;84(22):3728-3742. [Abstract]; Schematic image of selective YAP1 depletion model on Cd248-CreERT2; Yap1flox/flox mice by using Tamoxifen (120 mg/kg/day; i.p. for 5 d).

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102509.; Expression of TFRC in primary fibroblasts from TFRCflox/flox and TFRC−/− mice was assessed by western blot after 5 days of Tamoxifen intraperitoneal injection and 7 days of waiting.

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Immunity. 2020 Nov 17;53(5):1078-1094.e7. [Abstract]; Frequency of TdTomato-labelled cells in TdT-Jchain mice treated with Tamoxifen (mice; 50 mg/kg； oral gavage; for two consecutive days) 14 and 15 days after WNV vaccination was analyzed by flow cytometry 13 days later (28 days after WNV vaccination) and compared to week 1 labeling.

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]; Representative fields, intracellular TG contents and secreted TG of female C57BL/6 mice hepatocytes treated with C29, Tamoxifen (20 μM; 36 h), Toremifene and 4-OHT. LDs were labeled with Nile Red (red).

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]; Representative images of liver tissue (top), sections stained with Oil Red O (bottom) and liver TG levels from Ad-ERRα or Ad-Ctrl-injected female mice treated with TMX (100 mg/kg; p.o. for 5 days).

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]; Different transmission of MAPK8/FoxO signaling pathway in breast cancer cells (MCF-7, T47D, ZR-75, and MDA-MB-231) and liver cells (LO2) exposed to TAM (Tamoxifen).

: Tamoxifen Citrate purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]; Tamoxifen inhibits the growth and metastasis of prostate tumors in vivo. Western blot analysis of the indicated proteins in prostate primary tumors tissues.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All Isoforms

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

View All HSP Isoform Specific Products:

View All Isoforms

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[4]

Estrogen receptor

HSP90

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	ED₅₀	7 μg/mL Compound: TAM	Effective dose for reduction in cell growth of human skin cancer A431 cell line Effective dose for reduction in cell growth of human skin cancer A431 cell line	[PMID: 15509181]
DU-145	IC₅₀	11.2 μM Compound: Tam citrate	Anticancer activity against human DU-145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human DU-145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
DU-145	IC₅₀	15.25 μM Compound: Tamoxifen citrate	Cytotoxicity against human DU145 cells after 18 hrs by MTT assay Cytotoxicity against human DU145 cells after 18 hrs by MTT assay	[PMID: 19932024]
HEK293	IC₅₀	27.3 μM Compound: Tam citrate	Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
HEK293	IC₅₀	30 μM Compound: Tamoxifen citrate	Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 29352645]
Ishikawa	IC₅₀	12.5 μM Compound: Tamoxifen citrate	Cytotoxicity against human Ishikawa cells after 18 hrs by MTT assay Cytotoxicity against human Ishikawa cells after 18 hrs by MTT assay	[PMID: 19932024]
KB	ED₅₀	9 μg/mL Compound: TAM	Dose required for reduction in cell growth of human nasopharyngeal carcinoma KB cell line Dose required for reduction in cell growth of human nasopharyngeal carcinoma KB cell line	[PMID: 15509181]
KB	ED₅₀	9 μg/mL Compound: TAM	Dose required for reduction in cell growth of vincristine-resistant human nasopharyngeal carcinoma KB cell line Dose required for reduction in cell growth of vincristine-resistant human nasopharyngeal carcinoma KB cell line	[PMID: 15509181]
LNCaP	ED₅₀	6 μg/mL Compound: TAM	Dose required for reduction in cell growth of human AR-dependent prostate cancer LN-CaP cell line Dose required for reduction in cell growth of human AR-dependent prostate cancer LN-CaP cell line	[PMID: 15509181]
MCF7	ED₅₀	5 μg/mL Compound: TAM	Dose required for reduction in cell growth of estrogen positive human breast cancer MCF-7 cell line (ER+) Dose required for reduction in cell growth of estrogen positive human breast cancer MCF-7 cell line (ER+)	[PMID: 15509181]
MCF7	IC₅₀	0.796 μM Compound: Tamoxifen citrate	Inhibition of 17-beta estradiol-induced cell proliferation in human MCF7 cells incubated for 6 days by acid red-52 staining based assay Inhibition of 17-beta estradiol-induced cell proliferation in human MCF7 cells incubated for 6 days by acid red-52 staining based assay	[PMID: 28882502]
MCF7	IC₅₀	10.2 μM Compound: Tamoxifen citrate	Cytotoxicity against human MCF7 cells after 18 hrs by MTT assay Cytotoxicity against human MCF7 cells after 18 hrs by MTT assay	[PMID: 19932024]
MCF7	IC₅₀	13.7 μM Compound: Tamoxifen citrate	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 29352645]
MCF7	IC₅₀	6.2 μM Compound: Tam citrate	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
MCF7	IC₅₀	9.53 μM Compound: Tamoxifen citrate	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 32947093]
MDA-MB-231	ED₅₀	8 μg/mL Compound: TAM	Dose required for reduction in cell growth of estrogen negative human breast cancer MDA-MB-231 cell line (ER-) Dose required for reduction in cell growth of estrogen negative human breast cancer MDA-MB-231 cell line (ER-)	[PMID: 15509181]
MDA-MB-231	IC₅₀	10.71 μM Compound: Tamoxifen citrate	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 32947093]
MDA-MB-231	IC₅₀	12.3 μM Compound: Tamoxifen citrate	Cytotoxicity against human MDA-MB-231 cells after 18 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 18 hrs by MTT assay	[PMID: 19932024]
MDA-MB-231	IC₅₀	12.8 μM Compound: Tam citrate	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
MDA-MB-231	IC₅₀	17.9 μM Compound: Tamoxifen citrate	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 29352645]
PC-3	ED₅₀	10 μg/mL Compound: TAM	Dose required for reduction in cell growth of human prostate cancer PC-3 cell line Dose required for reduction in cell growth of human prostate cancer PC-3 cell line	[PMID: 15509181]
PC-3	IC₅₀	11.7 μM Compound: Tam citrate	Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
SK-BR-3	ED₅₀	5 μg/mL Compound: TAM	Dose required for reduction in cell growth of estrogen negative human breast cancer SK-BR-3 cell line(ER-) Dose required for reduction in cell growth of estrogen negative human breast cancer SK-BR-3 cell line(ER-)	[PMID: 15509181]
SW-620	ED₅₀	4 μg/mL Compound: TAM	Dose required for reduction in cell growth of human colon cancer SW620 cell line Dose required for reduction in cell growth of human colon cancer SW620 cell line	[PMID: 15509181]
Vero C1008	CC₅₀	37.96 μM Compound: Tamoxifen Citrate	CC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells CC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells	10.1101/2020.03.25.008482
Vero C1008	CC₅₀	37.96 μM Compound: Tamoxifen Citrate	CC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells CC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in Vero E6 cells	10.1101/2020.03.25.008482
Vero C1008	IC₅₀	34.12 μM Compound: Tamoxifen Citrate	IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells	10.1101/2020.03.25.008482
Vero C1008	IC₅₀	8.98 μM Compound: Tamoxifen Citrate	IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells	10.1101/2020.03.25.008482
ZR-75-1	ED₅₀	5 μg/mL Compound: TAM	Dose required for reduction in cell growth of estrogen positive human breast cancer ZR-75-1 cell line (ER+) Dose required for reduction in cell growth of estrogen positive human breast cancer ZR-75-1 cell line (ER+)	[PMID: 15509181]

In Vitro

Tamoxifen Citrate (ICI 46474) shows strong inhibition of MCF-7 cells (EC₅₀=1.41 μM) and to a lesser extent the T47D cells (EC₅₀=2.5 μM) but does not affect the MDA-MB-231 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Note: Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

1. Induction of gene knockout^[7]^[8]

Background

Gene knockout model induced by Tamoxifen Citrate uses Cre-Loxp mice. The Cre recombinase in these mice is driven by a tissue/cell-specific promoter, and the target gene is flanked by Loxp sites. The Cre recombinase is fused with the ligand-binding domain of the estrogen receptor to construct a Cre-ER fusion protein, and the recombination activity of Cre is induced by Tamoxifen Citrate. In the absence of Tamoxifen Citrate, the Cre-ER fusion protein binds to HSP90 and remains in the cytoplasm. After Tamoxifen Citrate induction, the metabolite of Tamoxifen Citrate, 4-OHT, binds to the Cre-ER protein, activates the Cre recombinase, and allows it to enter the nucleus. There, it recognizes the Loxp sites and mediates the knockout of the gene between two (in the same orientation) Loxp sites. (To avoid interference from endogenous estrogens, the ligand-binding domain of the estrogen receptor is modified, transforming Cre-ER into MerCreMer, Cre-ERT, or Cre-ERT2).

Specific Modeling Methods

Cx3cr1^CreERT/+: Pdgfb^fl/fl mice (Conditional knockout of Pdgfb in microglia)
Administration: 75 mg/kg • i.p. • once daily for 5 consecutive days

Note

(1) Dissolution: Tamoxifen is poorly soluble in water and is generally dissolved in Corn oil (HY-Y1888). It can be heated at 37°C or sonicated to assist dissolution, ensuring complete dissolution. Tamoxifen should be prepared in the dark and is recommended to be used freshly prepared. Corn oil is relatively viscous. When aspirating the solution, the needle can be left unplugged. After aspirating the solution, attach the needle and expel the air bubbles.
(2) Administration methods: Common methods include intraperitoneal injection, and it can also be administered by oral gavage or subcutaneous injection. When performing multiple intraperitoneal injections, the injection sites should be alternated.
(3) Dosage: The dosage is 50-120 mg/kg, with 3-5 intraperitoneal injections, usually for 5 consecutive days. The dosage for pregnant mice and aged mice (over 6 months old) should be appropriately reduced. Tamoxifen can affect fetal development and parturition. For pregnant mice, the induction time should preferably be selected in the late pregnancy stage, and progesterone should be injected simultaneously to reduce the probability of miscarriage.
(4) Mice: Mice at 4-6 weeks old may be more sensitive (it is more effective in young mice than in old mice).
(5) Potential toxicity: Prolonged high-level Cre activity can cause potential toxicity. In addition, if an important functional gene is knocked out or using Homozygous Mice, it may also lead to the death of mice. Therefore, close observation should be carried out within one or two weeks after induction. If the mice show abnormalities, the causes need to be analyzed in a timely manner and the experimental plan should be adjusted.
(6) Control: Control group mice should be injected with an equal amount of the corn oil solution of Tamoxifen (using Tamoxifen in a genetic background without Cre recombinase) to rule out the influence of Tamoxifen itself.
(7) Detection window: The time window between Tamoxifen administration and the start of the experiment should be large enough, at least 7 days, to ensure that the Cre recombinase enters the nucleus and functions.
(8) Separate caging: Animals treated with Tamoxifen should be caged separately from untreated animals to avoid cross - contamination caused by behaviors such as animals licking the oily Tamoxifen suspension, grooming their fur, or coprophagy.

Modeling Indicators

Verify the reduced expression/knockout of the target gene at the RNA or protein level through molecular biology and genetic methods (such as Western blot, PCR, and sequencing, etc.).

Correlated Product(s): 4-Hydroxytamoxifen (HY-16950)

2. Induction of liver injury^[9]^[10]

Background

Tamoxifen Citrate reduces the hexose monophosphate shunt, thereby increasing the incidence of oxidative stress in rat hepatocytes, leading to liver injury.

Specific Modeling Methods

Albino rat • female
Administration: 45 mg/kg • i.p. • once daily for 7 days

Note

(1) The rats were kept in a standard laboratory environment, which was a 12-hour light/12-hour dark cycle with the temperature maintained at 25 ± 2°C. They had free access to food and water.
(2) At the end of the experiment, the animals were euthanized by cervical dislocation under mild ether anesthesia. The blood samples were collected in heparinized centrifuge tubes and centrifuged to obtain serum. The abdomen was opened, and the liver was immediately dissected and removed. It was washed with ice-cold isotonic saline and blotted between two filter papers. The liver was wrapped in aluminum foil and stored at -80°C. A 10% (w/v) liver homogenate was prepared in ice-cold 0.1 M potassium phosphate buffer (pH 7.5) using an ultrasonicator.

Modeling Indicators

Molecular Changes: The activities of antioxidant enzymes, including glutathione S-transferase, glutathione peroxidase, and catalase, were significantly ↓, while the content of reduced glutathione also showed a ↓ trend. Concurrently, the levels of thiobarbituric acid reactive substances (TBARS) and liver transaminases, including serum glutamic-pyruvic transaminase (sGPT) and serum glutamic-oxaloacetic transaminase (sGOT), were significantly ↑.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

563.64

Formula

C₃₂H₃₇NO₈

CAS No.

54965-24-1

Appearance

Solid

Color

White to off-white

SMILES

CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (88.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (17.74 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7742 mL	8.8709 mL	17.7418 mL
5 mM	0.3548 mL	1.7742 mL	3.5484 mL
10 mM	0.1774 mL	0.8871 mL	1.7742 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.88%

Select Batch:

Data Sheet (296 KB) SDS (701 KB)

COA (256 KB) HNMR (276 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]

[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]

[3]. Jia Y, et al. Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal DilatedCardiomyopathy in Mice. PLoS One. 2016 Aug 22;11(8):e0160755. [Content Brief]

[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]

[5]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [Content Brief]

[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]

[7]. Bi Q, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. Immunity. 2022 Aug 9;55(8):1466-1482.e9. [Content Brief]

[8]. Chen MY, et al. A review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study. Biomed Pharmacother. 2023 Sep;165:115045. [Content Brief]

[9]. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38(5):563-70. [Content Brief]

[10]. El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38(3): 300-306. [Content Brief]

Animal Administration
^[3]

Mice^[3]
Seven-week old TmcsMed1^-/- mice and the wild-type littermates are then administered Tamoxifen intraperitoneally at a daily dose of 65 mg/kg body weight for 5 days and then killed at selected intervals after initiation of Tamoxifen treatment. For each experiment 3 to 5 mice for control and csMed1^-/- are used. To obtain survival curve 41 csMed1^-/- and 41 csMed1^fl/fl mice are used. Thirteen TmcsMed^-/- mice and the same number of littermates are used for the survival curve experiments using Tamoxifen inducible model.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]

[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]

[3]. Jia Y, et al. Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal DilatedCardiomyopathy in Mice. PLoS One. 2016 Aug 22;11(8):e0160755. [Content Brief]

[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]

[5]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [Content Brief]

[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]

[7]. Bi Q, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. Immunity. 2022 Aug 9;55(8):1466-1482.e9. [Content Brief]

[8]. Chen MY, et al. A review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study. Biomed Pharmacother. 2023 Sep;165:115045. [Content Brief]

[9]. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38(5):563-70. [Content Brief]

[10]. El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38(3): 300-306. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	1.7742 mL	8.8709 mL	17.7418 mL	44.3546 mL
	5 mM	0.3548 mL	1.7742 mL	3.5484 mL	8.8709 mL
	10 mM	0.1774 mL	0.8871 mL	1.7742 mL	4.4355 mL
	15 mM	0.1183 mL	0.5914 mL	1.1828 mL	2.9570 mL
DMSO	20 mM	0.0887 mL	0.4435 mL	0.8871 mL	2.2177 mL
	25 mM	0.0710 mL	0.3548 mL	0.7097 mL	1.7742 mL
	30 mM	0.0591 mL	0.2957 mL	0.5914 mL	1.4785 mL
	40 mM	0.0444 mL	0.2218 mL	0.4435 mL	1.1089 mL
	50 mM	0.0355 mL	0.1774 mL	0.3548 mL	0.8871 mL
	60 mM	0.0296 mL	0.1478 mL	0.2957 mL	0.7392 mL
	80 mM	0.0222 mL	0.1109 mL	0.2218 mL	0.5544 mL

Tamoxifen Citrate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Tamoxifen Citrate (Synonyms: ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate)

Customer Review

Other Forms of Tamoxifen Citrate:

229 Publications Citing Use of MCE Tamoxifen Citrate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All HSP Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tamoxifen Citrate Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tamoxifen Citrate (Synonyms: ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate)

Customer Review

Other Forms of Tamoxifen Citrate:

Tamoxifen Citrate Related Antibodies

229 Publications Citing Use of MCE Tamoxifen Citrate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Estrogen Receptor/ERR Isoform Specific Products:

View All HSP Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Tamoxifen Citrate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tamoxifen Citrate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report